GeoVax Announces Upcoming Presentations at Scientific Conferences
November 15, 2021 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update
November 11, 2021 16:00 ET
|
GeoVax, Inc.
Progress in Clinical Development of COVID-19 and Immuno-Oncology ProgramsATLANTA, GA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-19 Vaccine
November 09, 2021 16:00 ET
|
GeoVax, Inc.
Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVax’s Pan-Coronavirus Vaccine Program ATLANTA, GA and DUARTE, CA, Nov. 09, 2021 (GLOBE NEWSWIRE)...
GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update
November 04, 2021 09:00 ET
|
GeoVax, Inc.
Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the...
GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe
October 18, 2021 09:00 ET
|
GeoVax, Inc.
GEO-CM02 Progresses as a Universal Coronavirus Vaccine Candidate ATLANTA, GA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Receives Notice of Allowance for Ebola Vaccine Patent
October 14, 2021 09:00 ET
|
GeoVax, Inc.
Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation Atlanta, GA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program
September 28, 2021 16:00 ET
|
GeoVax, Inc.
License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers ATLANTA, GA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 07, 2021 09:00 ET
|
GeoVax, Inc.
Atlanta, GA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today...
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
August 19, 2021 16:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021
August 12, 2021 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and...